Is this you? Create Your Porfile
Avatar

Karl Schonafinger

Aventis Pharma

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Karl Schonafinger is active.

Explore More

Publication

Featured researches published by Karl Schonafinger.

Molecular Pharmacology | 2006

Biochemistry and Pharmacology of Novel Anthranilic Acid Derivatives Activating Heme-Oxidized Soluble Guanylyl Cyclase

Ursula Schindler; Hartmut Strobel; Karl Schonafinger; Wolfgang Linz; Matthias Löhn; Piero Martorana; Hartmut Rütten; Peter Schindler; Andreas E. Busch; Michael Sohn; Andrea Töpfer; Astrid Pistorius; Christoph Jannek; Alexander Mülsch

Archive | 1999

Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them

Ursula Schindler; Karl Schonafinger; Hartmut Strobel

Archive | 2002

Acylated indanyl amines and their use as pharmaceuticals

Hartmut Strobel; Paulus Wohlfart; Alena Safarova; Armin Walser; Teri Suzuki; Karl Schonafinger; Ramalinga M. Dharanipragada

Archive | 1998

Pyrazole derivatives, their preparation and their use in pharmaceuticals

Ursula Schindler; Karl Schonafinger; Hartmut Strobel

Archive | 1995

2-Amino-1,3-thiazines as nitric oxide synthase inhibitors

Hartmut Strobel; Helmut Bohn; Peter Klemm; Otmar Klingler; Ursula Schindler; Karl Schonafinger; Gerhard Zoller

Archive | 1998

Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments

Ursula Schindler; Karl Schonafinger; Hartmut Strobel; Peter Schindler

Archive | 1998

Pyrazole derivatives, their preparation and their use in drugs

Ursula Schindler; Karl Schonafinger; Hartmut Strobel

Archive | 1983

Substituted 1,4-dihydropyridines and their use as medicaments

Karl Schonafinger; Helmut Bohn; Melitta Just; Piero Martorana

Archive | 1983

SUBSTITUTED 1,2,5-OXADIAZOLE-2-OXIDES FOR USE AS MEDICAMENTS AND MEDICAMENTS CONTAINING THEM

Karl Schonafinger; Rudi Beyerle; Anton Mogilev; Helmut Bohn; Piero Dr. Martorana; Rolf-Eberhard Nitz

Archive | 1993

Use of 2-(N-(2-aminoethyl)amino)acetic acid derivatives for the treatment of diseases which are mediated by non-enzymatical glycosylation

Karl Schonafinger; Ursula Schindler; Eckhard Schraven

Explore More

Collaboration

Dive into the Karl Schonafinger's collaboration.

Top Co-Authors
Avatar

Helmut Bohn

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Ursula Schindler

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Hartmut Strobel

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Melitta Just

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Joachim Brendel

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Gerhard Zoller

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Otmar Klingler

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Volker B. Fiedler

Bayer

View shared research outputs
Top Co-Authors
Avatar

Alena Safarova

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Armin Walser

Aventis Pharma

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge